Trends in qualifying biomarkers in drug safety. Consensus of the 2011 meeting of the Spanish Society of Clinical Pharmacology

被引:12
作者
Agundez, Jose A. G. [1 ,2 ]
del Barrio, Jaime [3 ]
Padro, Teresa [4 ,5 ]
Stephens, Camilla [6 ,7 ]
Farre, Magi [8 ]
Andrade, Raul J. [7 ,9 ]
Badimon, Lina [4 ,5 ]
Garcia-Martin, Elena [2 ,10 ]
Vilahur, Gemma [4 ,5 ]
Isabel Lucena, M. [6 ,7 ]
机构
[1] Univ Extremadura, Dept Pharmacol, Avda Univ S-N, E-10071 Caceres, Spain
[2] Red Invest Reacciones Adversas Alergenos & Farm, Caceres, Spain
[3] Roche Inst, Madrid, Spain
[4] Biomed Res Inst St Pau, CSIC ICCC, Cardiovasc Res Ctr, Barcelona, Spain
[5] Ctr Invest Biomed Red Fisiopatol Obesidad & Nutr, Madrid, Spain
[6] Hosp Univ Virgen Victoria, Fac Med, Clin Pharmacol Serv, Malaga, Spain
[7] Ctr Invest Biomed Red Enfermedades Hepat & Digest, Barcelona, Spain
[8] Univ Autonoma Barcelona, Hosp Mar Res Inst IMIM, E-08193 Barcelona, Spain
[9] Hosp Univ Virgen Victoria, Fac Med, Liver Unit, Malaga, Spain
[10] Univ Extremadura, Dept Biochem & Mol Biol, E-10071 Caceres, Spain
来源
FRONTIERS IN PHARMACOLOGY | 2012年 / 3卷
关键词
biomarkers; pharmacogenomics; drug-induced liver injury; drug safety; PHARMACOGENETICS IMPLEMENTATION CONSORTIUM; INDUCED LIVER-INJURY; THIOPURINE METHYLTRANSFERASE; GENOTYPE; GUIDELINES; SUSCEPTIBILITY; POLYMORPHISMS; PHENOTYPE; MEDICINE; CYP2C19;
D O I
10.3389/fphar.2012.00002
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
In this paper we discuss the consensus view on the use of qualifying biomarkers in drug safety, raised within the frame of the XXIV meeting of the Spanish Society of Clinical Pharmacology held in Malaga (Spain) in October, 2011. The widespread use of biomarkers as surrogate endpoints is a goal that scientists have long been pursuing. Thirty years ago, when molecular pharmacogenomics evolved, we anticipated that these genetic biomarkers would soon obviate the routine use of drug therapies in a way that patients should adapt to the therapy rather than the opposite. This expected revolution in routine clinical practice never took place as quickly nor with the intensity as initially expected. The concerted action of operating multicenter networks holds great promise for future studies to identify biomarkers related to drug toxicity and to provide better insight into the underlying pathogenesis. Today some pharmacogenomic advances are already widely accepted, but pharmacogenomics still needs further development to elaborate more precise algorithms and many barriers to implementing individualized medicine exist. We briefly discuss our view about these barriers and we provide suggestions and areas of focus to advance in the field.
引用
收藏
页数:6
相关论文
共 32 条
[1]   Unraveling ambiguous NAT2 genotyping data [J].
Agundez, Jose A. G. ;
Golka, Klaus ;
Martinez, Carmen ;
Selinski, Silvia ;
Blaszkewicz, Meinolf ;
Garcia-Martin, Elena .
CLINICAL CHEMISTRY, 2008, 54 (08) :1390-1394
[2]   Assessment of nonsteroidal anti-inflammatory drug-induced hepatotoxicity [J].
Agundez, Jose A. G. ;
Isabel Lucena, Maria ;
Martinez, Carmen ;
Andrade, Raul J. ;
Blanca, Miguel ;
Ayuso, Pedro ;
Garcia-Martin, Elena .
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2011, 7 (07) :817-828
[3]  
Agúndez JAG, 2009, EXPERT OPIN DRUG MET, V5, P607, DOI [10.1517/17425250902970998 , 10.1517/17425250902970998]
[4]   Pharmacogenomics in Drug Induced Liver Injury [J].
Andrade, Raul J. ;
Agundez, Jose A. G. ;
Isabel Lucena, M. ;
Martinez, Carmen ;
Cueto, Raquel ;
Garcia-Martin, Elena .
CURRENT DRUG METABOLISM, 2009, 10 (09) :956-970
[5]  
[Anonymous], PUBL HLTH ER GEN BAS
[6]   Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework [J].
Atkinson, AJ ;
Colburn, WA ;
DeGruttola, VG ;
DeMets, DL ;
Downing, GJ ;
Hoth, DF ;
Oates, JA ;
Peck, CC ;
Schooley, RT ;
Spilker, BA ;
Woodcock, J ;
Zeger, SL .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 69 (03) :89-95
[7]   HLA-B☆5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin [J].
Daly, Ann K. ;
Donaldson, Peter T. ;
Bhatnagar, Pallav ;
Shen, Yufeng ;
Pe'er, Itsik ;
Floratos, Aris ;
Daly, Mark J. ;
Goldstein, David B. ;
John, Sally ;
Nelson, Matthew R. ;
Graham, Julia ;
Park, B. Kevin ;
Dillon, John F. ;
Bernal, William ;
Cordell, Heather J. ;
Pirmohamed, Munir ;
Aithal, Guruprasad P. ;
Day, Christopher P. .
NATURE GENETICS, 2009, 41 (07) :816-U71
[8]   Integrating molecular medicine into the US health-care system: Opportunities, barriers, and policy challenges [J].
Deverka, P. A. ;
Doksum, T. ;
Carlson, R. J. .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2007, 82 (04) :427-434
[9]  
European Medicines Agency, 2009, EMACHMPICH3806362009
[10]  
Food and Drug Administration, 2011, TABL PHARM BIOM DRUG